Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
Author:
Funder
Else Kröner-Fresenius-Stiftung
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/article/10.1007/s00432-018-2807-1/fulltext.html
Reference35 articles.
1. Barlogie B, Alexanian R, Gehan EA, Smallwood L, Smith T, Drewinko B (1983) Marrow cytometry and prognosis in myeloma. J Clin Invest 72:853–861. https://doi.org/10.1172/JCI111056
2. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA (2001) 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 181:234–249
3. Chim CS et al (2017) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. https://doi.org/10.1038/leu.2017.329
4. Chng WJ et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269–277. https://doi.org/10.1038/leu.2013.247
5. Clave E et al (2014) Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 55:1788–1795. https://doi.org/10.3109/10428194.2013.865182
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK;Infectious Diseases and Therapy;2024-04-24
2. Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report;Oncology Letters;2024-04-03
3. Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma;Frontiers in Cell and Developmental Biology;2024-02-12
4. Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study;Acta Haematologica;2022-12-20
5. Advances in the treatment of extramedullary disease in multiple myeloma;Translational Oncology;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3